Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2019 16:05 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Host R&D Day on March 26, 2019

Company to highlight next-generation, novel programmed T cell therapies in development for hematological and solid tumor indications Program and webcast to begin at 8:00 am ET LONDON, March 07,...
March 04, 2019 16:05 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference

LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
March 04, 2019 06:30 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present New Data on AUTO1 at the American Association of Cancer Research (AACR) Annual Meeting 2019

LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
June 26, 2018 09:15 ET | Source: AUTOLUS LIMITED

Autolus Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

Autolus Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares LONDON – 26 June 2018 – Autolus Therapeutics plc...
June 21, 2018 21:52 ET | Source: AUTOLUS LIMITED

Autolus Announces Pricing of Initial Public Offering

Autolus Announces Pricing of Initial Public Offering LONDON – 22 June, 2018 – Autolus Therapeutics plc (“Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T...
September 26, 2017 03:29 ET | Source: AUTOLUS LIMITED

AUTOLUS LIMITED: Autolus Secures US$80 million Series C Funding

Autolus Secures US$80 million Series C Funding Proceeds will be used to establish clinical proof of concept for three novel haematological cancer programs London, 26 September 2017 -...